搜索筛选:
搜索耗时0.1219秒,为你在为你在102,285,761篇论文里面共找到 3 篇相符的论文内容
发布年度:
[期刊论文] 作者：Kai-li Zhang,Qian-qian Shen,Yan-fen Fang,Yi-ming Sun,Jian Ding,Yi Chen,
来源：中国药理学报（英文版） 年份：2019
Deregulated Polycomb repressive complex 2 (PRC2) is intimately involved in tumorigenesis and progression,making it an invaluable target for epigenetic cancer th...
[期刊论文] 作者：Xiao-ping CHAI,Guang-long SUN,Yan-fen FANG,Li-hong HU,Xuan LIU,Xiong-wen ZHANG,
来源：中国药理学报（英文版） 年份：2018
BF211,a bufalin (BF) derivative,exhibits stronger anti-cancer activity than BF but with potential cardiotoxicity.Fibroblast activation protein-α (FAPα) is a m...
SAF-189s,a potent new-generation ROS1 inhibitor,is active against crizotinib-resistant ROS1 mutant-d
[期刊论文] 作者：Zong-jun Xia,Yin-chun Ji,De-qiao Sun,Xia Peng,Ying-lei Gao,Yan-fen Fang,Xing-dong Zhao,Wei-bo Wang,Jian,
来源：中国药理学报（英文版） 年份：2021
The ROS1 fusion kinase is an attractive antitumor target.Though with significant clinical efficacy,the well-known first-generation ROS1 inhibitor(ROS1 i)crizotinib inevitably developed acquired resistance due to secondary point mutations in......
相关搜索：
